Personalized alemtuzumab dosing for patients having allogeneic bone marrow transplants
Precision Alemtuzumab Therapy in Allogeneic HCT
['FUNDING_R01'] · CINCINNATI CHILDRENS HOSP MED CTR · NIH-11140380
This project uses personalized alemtuzumab dosing for children and young adults having allogeneic bone marrow transplants to lower the risk of graft failure and graft-versus-host disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CINCINNATI CHILDRENS HOSP MED CTR (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-11140380 on ClinicalTrials.gov |
What this research studies
If you are a child or young adult needing an allogeneic hematopoietic cell transplant for non-malignant diseases, researchers will measure alemtuzumab blood levels around the time of transplant and relate those levels to outcomes. They will compare dosing approaches and aim for target peri-transplant concentrations (around 0.2–0.6 mcg/mL on the day of graft) to find the best dose for each patient. Dosing decisions will consider age, body size, and blood counts to balance preventing graft rejection with avoiding excessive immune suppression. The goal is to help the donor graft take while reducing severe graft-versus-host disease and infection risk.
Who could benefit from this research
Good fit: Ideal candidates are children and young adults undergoing allogeneic hematopoietic cell transplantation who will receive reduced-intensity or reduced-toxicity conditioning that includes alemtuzumab.
Not a fit: Patients who do not receive alemtuzumab as part of their conditioning, those outside the pediatric/young-adult population, or those on different transplant regimens are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, this could lower graft failure and serious graft-versus-host disease while reducing infection risk by tailoring alemtuzumab doses to each patient.
How similar studies have performed: Previous studies have identified target peri-transplant alemtuzumab levels and associations with outcomes, but personalized pediatric dosing strategies are relatively new.
Where this research is happening
CINCINNATI, UNITED STATES
- CINCINNATI CHILDRENS HOSP MED CTR — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEHTA, PARINDA A. — CINCINNATI CHILDRENS HOSP MED CTR
- Study coordinator: MEHTA, PARINDA A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Graft Versus Host Disease, Acute Radiation Syndrome